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Abstract
We describe three invasive mould infections due to Hormographiella aspergillata occurring within 1 year in patients undergoing treatment
for acute leukaemia. All patients presented with pulmonary inﬁltrates; one patient additionally had cerebral and ocular involvement.
Diagnostic procedures included bronchoalveolar lavage in all, and video-assisted thoracoscopic surgery in two patients. Susceptibility
testing was performed by E-test and detected low minimal inhibitory concentrations for voriconazole and amphotericin B. All patients
received systemic antifungal therapy; however, all of them died. Despite this cluster of three cases of an unusual mould infection, no
hospital source was detected.
Keywords: Chemotherapy, leukaemia, mould infection, non-Aspergillus mould, stem cell transplantation
Original Submission: 15 February 2010; Revised Submission: 17 April 2010; Accepted: 29 April 2010
Editor: E. Roilides
Article published online: 18 May 2010
Clin Microbiol Infect 2011; 17: 273–277
10.1111/j.1469-0691.2010.03266.x
Corresponding author: A. Conen, MD, Cantonal Hospital Aarau,
Tellstrasse, CH-5001 Aarau, Switzerland
E-mail: anna.conen@ksa.ch
Introduction
Invasive fungal infections are a major cause of morbidity and
mortality in haematological patients undergoing chemo-
therapy or hematopoietic stem cell transplantation (HSCT)
for acute leukaemia [1]. In recent years, emergence of non-
Aspergillus moulds such as Zygomycetes, Fusarium, Scedospo-
rium, and Basidiomycetes has been observed. Whether the
increasing use of broad-spectrum antifungal prophylaxis with
newer azoles plays a role in this evolution remains unclear.
Other possible explanations are the introduction of molecu-
lar biology techniques allowing the exact identiﬁcation of
moulds and reporting bias. Hormographiella aspergillata is the
asexual form of Coprinus cinereus (recently reclassiﬁed as Co-
prinopsis cinerea), a non-Aspergillus mould belonging to the
class of Basidiomycetes that occurs in compost and sewage
and has previously been implicated in human infections on
only a few occasions. Five individual cases in patients after
chemotherapy for a haematological malignancy have been
reported over the course of 10 years [2–6]. In the present
study, we describe three cases of invasive H. aspergillata infec-
tion occurring within 1 year at our institution.
Hospital Setting
The isolation ward at the Division of Haematology at Basel
University Hospital contains twelve single-bed rooms
equipped with special high-efﬁciency particle air ﬁlters. Each
year, approximately 50 allogeneic transplants, 40 autologous
transplants and 50 cycles of chemotherapy for acute leukae-
mia are performed. According to infection surveillance data,
34 probable/proven invasive mould infections were diagnosed
between 2003 and 2008, giving an annual rate of approxi-
mately ﬁve or six cases (Weisser M, Blattler L, Elzi L, et al,
unpublished data). Antimicrobial prophylaxis consisted of co-
trimoxazole, ﬂuconazole and, in the case of positive herpes
simplex virus serology, valacyclovir. No primary prophylaxis
against moulds was administered. Screening for mould infec-
tions was performed by twice-weekly measurement of serum
galactomannan (Platelia Aspergillus; Bio-Rad Laboratories,
Hercules, CA, USA; using the standard cut-off value of ‡0.5
optical densities) and weekly pulmonary computed tomo-
graphy (CT) scanning. Surveillance fungal cultures of air
ﬁlters and ﬂoor specimens were carried out monthly.
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Microbiological Investigations
Blood cultures were performed by use of the BacT/ALERT
system (bioMe´rieux, Hazelwood, MO, USA) and a pair of
aerobic/anaerobic bottles (FA/FN). For fungal cultures from
other clinical specimens, Sabouraud agar containing chloram-
phenicol and gentamicin was inoculated and incubated for
3 weeks. Within 3–5 days of incubation, white to cream-col-
oured colonies were observed. Growth was faster at 37C
than at 28C. Microscopy of the aerial mycelium showed
septate conidiophores from which clusters of smooth-walled,
hyaline and cylindrical arthroconidia were produced (Fig. 1a).
In addition, clamps and, after 6 weeks of incubation, sclero-
tial bodies were observed. The identiﬁcation of H. aspergillata
was molecularly conﬁrmed in each patient by ampliﬁcation
and sequencing of the D2 region of large-subunit ribosomal
RNA gene using an ABI Prism 3130 sequencer and
MicroSEQ D2 LSU rDNA Fungal Identiﬁcation kit (Applied
Biosystems, Foster City, CA, USA) [7]. Susceptibility testing
was performed by E-test (AB Biodisk, Solna, Sweden) in
accordance with manufacturer’s instructions and the Clinical
and Laboratory Standards Institute (CLSI) [8].
Case 1
A 41-year-old female patient with acute myeloid leukaemia
(AML) was scheduled for double allogeneic peripheral blood
HSCT in October 2007. After conditioning with melphalan, a
ﬁrst T-cell depleted transplant from a human leukocyte
antigen-identical sibling donor was administered. Engraftment
was promptly achieved on day 9; however, the patient
rejected the ﬁrst transplant on day 15 and went on to a sec-
ond T-cell replete transplant after myeloablative conditioning.
On the day of the second transplant, the patient developed
neutropenic fever. A consolidation with halo sign suspicious
of invasive fungal infection was detected on pulmonary CT
scanning. Bronchoalveolar lavage (BAL) was carried out but
failed to reveal a causative microorganism. Serum galacto-
mannan levels were within the reference range. According to
local and national guidelines [9,10], an empirical treatment
for possible pulmonary mould infection with intravenous
voriconazole (4 mg/kg body weight twice-daily after loading
dose) was initiated. No serum levels of voriconazole were
performed to detect possible subtherapeutic serum levels.
Repeat CT on day 18 after the second transplant and 3 days
after engraftment showed progression of pulmonary
inﬁltrates. Antifungal therapy was empirically changed to oral
posaconazole (400 mg twice-daily). On day 24, acute graft-
versus-host disease (GvHD) grade III was diagnosed, and
methylprednisolone was started. Because of increasing liver
function tests under posaconazole therapy, antifungal treat-
ment was switched to caspofungin on day 30. Weekly CT
scans of the lungs showed lesions of constant size. On day
37, the patient developed amaurosis, and signs of intracranial
hypertension. Cranial CT scanning displayed extensive cere-
bellar haemorrhage, and the patient died on day 41. Autopsy
ﬁndings included extensive invasive mould infection of the
lungs, left eye and both cerebral hemispheres. A blood cul-
ture taken during autopsy grew H. aspergillata.
Case 2
A 63-year old female patient with secondary AML received
induction chemotherapy in August 2008. On day 23, the
patient developed neutropenic fever and a nonproductive
cough. Pulmonary CT showed nodular inﬁltrates. Treatment
with intravenous voriconazole for possible pulmonary mould
(a)
(b)
FIG. 1. (a) Lactophenol cotton blue tape-mount of Hormographiella
aspergillata culture displaying conidiophores and arthroconidia.
(b) Pulmonary computed tomography scan of patient two showing
bilateral ground glass inﬁltration and a pulmonary nodule compatible
with invasive mould infection.
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infection (4 mg/kg body weight twice-daily after loading dose)
was initiated. BAL and serum galactomannan testing were
negative. Nine days later, the second course of chemother-
apy was started. Follow-up CT showed a progression of the
pulmonary inﬁltrates. BAL was repeated and remained nega-
tive, as did galactomannan. Antifungal therapy was empirically
switched to oral posaconazole (400 mg twice-daily) in the
still neutropenic patient. Prior, voriconazole serum levels
were performed and demonstrated therapeutical serum lev-
els (1–5 mg/L). Pulmonary CT 2 weeks later showed sub-
stantial progression of inﬁltrates spreading to the
contralateral lung (Fig. 1b). Antifungal therapy was switched
to high-dose intravenous liposomal amphotericin B (5 mg/kg
body weight daily) and two of the largest pulmonary nodules
were operatively removed by video-assisted thoracoscopic
surgery (VATS). Histological evaluation of the pulmonary tis-
sue revealed angioinvasive hyphae. Microbiological culture
grew H. aspergillata (Fig. 1a). Based on in vitro susceptibility
testing and concomitant renal failure, antifungal treatment
was switched back to intravenous voriconazole (4 mg/kg
body weight twice-daily after loading dose), with therapeutic
serum levels thereafter. Under this treatment regimen, fol-
low-up pulmonary CT showed marked improvement after
recovery of haematological parameters, 2 months later.
Because the patient did not enter remission from her AML,
no further chemotherapy was administered and the patient
died from disease progression.
Case 3
A 55-year old male patient with relapsed AML was hospital-
ized for cord-blood transplantation in November 2007. Dur-
ing re-induction chemotherapy prior to cord-blood HSCT,
the patient had developed a proven pulmonary infection with
Aspergillus fumigatus, which was treated with intravenous
voriconazole (4 mg/kg body weight twice-daily after loading
dose) after operative resection. Pulmonary CT at admission
showed no signs of persistent fungal infection. After
myeloablative conditioning, double cord-blood transplanta-
tion was performed. The patient failed to engraft and there-
fore a second cord-blood transplant was scheduled after
reduced intensity conditioning. One day before the second
transplant, when the patient was still under treatment with
intravenous voriconazole, a routine CT scan showed a
pulmonary nodule, suspicious of invasive fungal infection.
Antifungal treatment was switched to high-dose intravenous
liposomal amphotericin B (5 mg/kg body weight) and
pulmonary wedge resection was performed. Prior, voriconaz-
ole serum levels were performed and were within the
therapeutic range (1–5 mg/L). Histological evaluation of the
pulmonary tissue showed angioinvasive hyphae and microbio-
logical cultures grew H. aspergillata. Antifungal treatment was
switched back to intravenous voriconazole (4 mg/kg body
weight twice-daily after loading dose) based on in vitro sus-
ceptibility testing results. Neutrophil engraftment occurred
on day 32 after the second transplant. Follow-up CT at this
time point showed persistent nodules in both lungs. Soon
thereafter, the patient developed multi-organ failure in the
context of acute GvHD to which he succumbed.
Discussion
We report three cases of pulmonary invasive mould infec-
tion with H. aspergillata in immunocompromised patients
treated for AML. All patients had undergone prolonged peri-
ods of severe neutropenia; in one patient cerebral and
ocular involvement was additionally found on autopsy. This
patient had positive blood cultures with H. aspergillata, an
unusual ﬁnding in invasive mould infections, which has espe-
cially been documented for invasive infections with Fusarium
spp., where 40–50% of blood cultures in disseminated infec-
tion are described to be positive [11]. To our knowledge,
this is the ﬁrst published case of fungaemia with H. aspergilla-
ta. Another remarkable ﬁnding is that one the three patients
in this series was co-infected with A. fumigatus (case 3). Of
the ﬁve patients previously described in the literature, co-
infection with another mould was documented in three
[2,5,6]. The reason for this is unclear; however, it is possible
that H. aspergillata infection occurs predominantly in patients
with very severe immunosuppression, comprising a popula-
tion at high risk of carrying concomitant infection with other
moulds.
BAL was carried out in all three patients after CT scan-
ning had shown pulmonary inﬁltrates, but failed to identify a
causative microorganism, conﬁrming its low sensitivity for
the diagnosis of invasive mould infection in immunocompro-
mised patients [12]. By contrast, specimens collected by
VATS grew H. aspergillata in both cases where it was per-
formed, corroborating the high diagnostic yield of this proce-
dure [13]. Serial serum galactomannan measurements
remained negative in all three patients. Galactomannan, a
component of the cell wall of Aspergillus spp., the most fre-
quent mould isolated in haematological patients, is not pro-
duced by non-Aspergillus moulds, and should not be used as
an isolated screening strategy for mould infection.
Because of the rarity of cases reported [2–6], there is
no established treatment for H. aspergillata. Standardized
antifungal susceptibility testing of ﬁlamentous fungi has been
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established only recently [8] and breakpoints with proven
clinical relevance have yet to be deﬁned. To date, in vitro
susceptibility data in ﬁlamentous fungi cannot be translated
into clinical practice without reservation. In all patients in this
series, in vitro antifungal susceptibility testing was performed
and showed low Minimal Inhibitory Concentrations (MIC) for
voriconazole and amphotericin B, whereas caspofungin and
ﬂuconazole revealed limited and no activity; the MIC for posa-
conazole could not be determined in two patients as a result
of distinct trailing growth within the inhibition zone, and dem-
onstrated an elevated MIC in one patient with 2 mg/L
(Table 1). These results are in line with three previously
described case reports [2,3,6] and with data generated from
isolates stemming from different natural substrates [14,15].
An evaluation of the in vivo efﬁcacy of the antifungal treat-
ment administered in this series is difﬁcult as a result of not
only the lack of autopsy in two patients, but also the pro-
gression of the underlying haematological disease with con-
secutive death: The ﬁrst patient died as a direct
consequence of fungal infection and was under treatment
with caspofungin at that time, after severe hepatotoxicity
due to azole treatment. Echinocandins are ineffective against
many non-Aspergillus moulds, including H. aspergillata [16];
however, in this case, the causative microorganism was only
identiﬁed and tested for susceptibility to antifungal agents
after the patient had died. Patients two and three showed
radiological improvement after treatment with second gener-
ation azoles but died from progression of the underlying hae-
matological disease and allogeneic transplant-related
complications, respectively, precluding a deﬁnitive appraisal
of the efﬁcacy of antifungal treatment administered.
The unusual cluster of three H. aspergillata cases at our
division prompted an epidemiological investigation, including
fungal cultures of environmental specimens and air particle
ﬁlters, although this did not detect a common source of
infection. All patients had been treated in different rooms
and stemmed from different regions within Switzerland. No
clear seasonality could be determined because of the small
case number in the series. In the 12 months following the
third case, no further infection with H. aspergillata was found;
therefore, a hospital source appears unlikely.
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